Melanoma patients treated with the combination of anti-LAG3 antibody Relatlimab and anti-PD-1 antibody Nivolumab have median progression-free survival of 10.1 months compared with 4.6 months with Nivolumab alone [79]. This evidence concerns the gene LAG3 and melanoma.